Johnson & Johnson (NYSE:JNJ) Stock Acquired Rep. Lisa C. McClain

Posted by Defense World Staff on Sep 17th, 2025

Representative Lisa C. McClain (R-Michigan) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on August 4th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $50,001 – $100,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 8/28/2025.
Purchased $1,001 – $15,000 in shares of ACI Worldwide (NASDAQ:ACIW) on 8/19/2025.
Purchased $1,001 – $15,000 in shares of HCA Healthcare (NYSE:HCA) on 8/19/2025.
Sold $1,001 – $15,000 in shares of Amedisys (NASDAQ:AMED) on 8/18/2025.
Purchased $1,001 – $15,000 in shares of Kite Realty Group Trust (NYSE:KRG) on 8/13/2025.
Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 8/13/2025.
Purchased $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/13/2025.
Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 8/13/2025.
Sold $1,001 – $15,000 in shares of US Foods (NYSE:USFD) on 8/13/2025.
Purchased $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 8/13/2025.

Johnson & Johnson Trading Down 0.5%

Johnson & Johnson stock opened at $176.48 on Wednesday. The business has a 50-day simple moving average of $171.67 and a two-hundred day simple moving average of $161.46. The company has a market cap of $425.02 billion, a P/E ratio of 18.87, a P/E/G ratio of 2.26 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC lifted its stake in Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after acquiring an additional 1,225,676 shares in the last quarter. Norges Bank acquired a new position in Johnson & Johnson during the 2nd quarter worth about $4,877,174,000. Northern Trust Corp increased its holdings in Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after purchasing an additional 130,645 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Johnson & Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. Guggenheim reiterated a “neutral” rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $176.29.

Read Our Latest Report on JNJ

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.